Rapid and sensitive detection of methicillin-resistant Staphylococcus aureus through the RPA-PfAgo system

Area of Science:

• Microbiology
• Molecular Diagnostics
• Biotechnology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a growing global health threat, increasing incidence and mortality rates.
• Accurate and rapid diagnostic methods are crucial for effective MRSA infection prevention and control.
• Existing diagnostic systems require improvement in speed and precision for timely clinical intervention.

Purpose of the Study:

• To develop and validate a novel nucleic acid testing platform for simultaneous detection of Staphylococcus aureus (S. aureus) and MRSA infection status.
• To integrate Pyrococcus furiosus Argonaute (PfAgo) with recombinase polymerase amplification (RPA) for enhanced diagnostic capabilities.
• To provide a rapid, specific, and sensitive tool for identifying MRSA infections in clinical settings.

Main Methods:

• Development of a novel assay platform integrating PfAgo with RPA technology.
• Design of the assay for simultaneous detection of the nuc and mecA genes specific to MRSA.
• Validation of the platform using 40 clinical isolates and comparison with the Vitek2-COMPACT system.

Main Results:

• The RPA-PfAgo platform achieved visual MRSA detection within 55 minutes.
• Demonstrated a low detection limit of 10^2 copies/μL with high specificity, distinguishing MRSA from other pathogens.
• Achieved a 95.0% accuracy rate in clinical isolate validation compared to the Vitek2-COMPACT system.

Conclusions:

• The RPA-PfAgo platform represents a superior diagnostic tool for MRSA detection, offering enhanced sensitivity and specificity.
• This innovative approach has the potential to significantly improve the diagnosis and management of MRSA infections.
• The platform's high accuracy and rapid turnaround time make it a valuable asset in combating MRSA.